Typewriter Therapeutics Raises USD 56 Million Series A to Advance TPRT RNA Gene Insertion Platform for In Vivo CAR-T and Liver Diseases
Typewriter Therapeutics announced the completion of a USD 56 million Series A financing to develop...
PIC
Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) China and Belief BioMed Inc. issued a...
Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double‑Digit Royalties
Keymed Biosciences Inc. (HKG: 2162) announced that it has entered into an exclusive licensing agreement...
Medtronic Invests USD 700 Million in Cornerstone Robotics, Wins Distribution Rights for Sentire Endoscopic Surgical Robot Outside the U.S.
Medtronic (NYSE: MDT) announced a strategic partnership with Cornerstone Robotics, including a strategic investment of...
Allergan Aesthetics’ SKINVIVE by Juvéderm Wins NMPA Approval for Perioral Wrinkles, Backed by 93.4% POLSS Responder Rate
Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, announced that its SKINVIVE by Juvéderm, an injectable...
Simcere Zaiming Licenses SIM0660 Trispecific Antibody to Roche in Up to USD 1.53 Billion Oncology Deal
Simcere Zaiming Pharmaceutical, an oncology-focused innovative drug company under Simcere Pharmaceutical (HKG: 2096), announced that...
Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent
Johnson & Johnson MedTech and Jiangsu CED Medical Technology Co., Ltd. (“CED Medical”) have signed...
WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies
WestGene Biopharma and CREATE Medicines, Inc. announced a strategic license and collaboration agreement combining CREATE’s...
Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103
Simnova Biotech announced the completion of a Series B financing round of nearly RMB 400...
Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline
Leaderna Therapeutics announced the completion of its Series A+ financing round, invested exclusively by Grand...
Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes
Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA)...
Takeda Wins FDA Approval for MIMRYLO, First‑in‑Class Hepcidin Mimetic for Polycythemia Vera
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the U.S. Food and Drug...
AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline
AusperBio announced the completion of a USD 120m Series C financing round, a substantial capital...
TÜV Rheinland and United Imaging Sign Strategic Cooperation MoU to Accelerate Global Market Access for Medical Devices
TÜV Rheinland Greater China and United Imaging Healthcare Co., LTD have signed a strategic cooperation...
Gilead’s Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen
Gilead Sciences, Inc. (NASDAQ: GILD) announced that the U.S. Food and Drug Administration (FDA) has...
Roivant’s Lisraya Wins FDA Approval as First Targeted Therapy for Dermatomyositis
Roivant (NASDAQ: ROIV) announced that the US Food and Drug Administration (FDA) has approved Lisraya...
Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked
Hansoh Pharmaceutical Group (HKG: 3692) released its interim results for the first half of 2026,...
HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%
China‑based HitGen Inc. (SHA: 688222) released its interim report for the first half of 2026,...
Junshi Biosciences Achieves First‑Ever Semiannual Profitability as Toripalimab Sales Surge 36%
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced its unaudited interim results for...
FDA Approves Revolution Medicines’ Rasonque (daraxonrasib), an Oral Multi‑Selective RAS(ON) Inhibitor, for Metastatic Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) has approved Revolution Medicines’ Rasonque (daraxonrasib) for the...